4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Hepatocellular Carcinoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 2145 ongoing clinical trials involving Hepatocellular Carcinoma
Of the 2145 trials,575 trials are in Phase II
Furthermore, 450 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Hepatocellular Carcinoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Hepatocellular Carcinoma, an Oncology Disorders. Asia-Pacific, North America, and Europe are some of the prominent regions engaged in Hepatocellular Carcinoma-related drug trials.

Hepatocellular Carcinoma related clinical trial sponsors

Sun Yat-sen University, National Cancer Institute US, FUDAN University, and Eastern Hepatobiliary Surgery Hospital are some of the notable clinical trial sponsors involved in Hepatocellular Carcinoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Hepatocellular Carcinoma

Pembrolizumab (Keytruda), Nivolumab (Opdivo, Opdyta), and Bevacizumab (Avastin) are among the key marketed drugs involving Hepatocellular Carcinoma.

Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. Keytruda is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration. Pembrolizumab is marketed for the treatment of Hepatocellular Carcinoma and several other indications including Esophageal Squamous Cell Carcinoma (ESCC), Bile Duct Cancer (Cholangiocarcinoma), Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Esophageal Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Cervical Cancer, Melanoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Head And Neck Cancer, Gastric Cancer, Bladder Cancer, Small-Cell Lung Cancer, Solid Tumor. Pembrolizumab was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, and Germany by Merck & Co Inc and its subsidiaries.

Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal antibody. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. Opdivo is formulated as solution and concentrate solution for intravenous route of administration. Nivolumab is marketed for the treatment of Hepatocellular Carcinoma and several other indications including Esophageal Squamous Cell Carcinoma (ESCC), Kidney Cancer (Renal Cell Cancer), Non-Small Cell Lung Cancer, Esophageal Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Melanoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Liver Cancer, Gastric Cancer, Small-Cell Lung Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma. Nivolumab was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, and Germany by Bristol-Myers Squibb Co and its subsidiaries.